The reciprocal finding, downregulation of cytokine/angiogenic mediators (IL6, VEGFA, TGFB1), should be interpreted in the context of GBM’s profoundly immunosuppressive microenvironment and the limited, often transient, benefit of targeting these processes clinically [51,52]. This evidence concerns the gene TGFB1 and glioblastoma.